<DOC>
	<DOC>NCT02016105</DOC>
	<brief_summary>The aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type psoriasis.</brief_summary>
	<brief_title>Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Men or women at least 18 years of age at time of screening Chronic plaquetype psoriasis diagnosed for at least 6 months before randomization Moderate to severe psoriasis as defined at baseline by: PASI score of 12 or greater Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 4) and, Body Surface Area affected by plaquetype psoriasis of 10% or greater Chronic plaquetype psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator. Forms of psoriasis other than chronic plaquetype Druginduced psoriasis Ongoing use of prohibited psoriasis treatments Previous exposure to adalimumab Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with adalimumab Other In/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>plaque type psoriasis</keyword>
	<keyword>equivalent efficacy</keyword>
	<keyword>safety and immunogenicity</keyword>
	<keyword>GP2017</keyword>
	<keyword>Humira®</keyword>
</DOC>